MENU
VSTM
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

VSTM stock forecast, quote, news & analysis

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
VSTM
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for VSTM with price predictions
Oct 21, 2026

VSTM in downward trend: price may drop because broke its higher Bollinger Band on October 20, 2026

VSTM broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 43 similar instances where the stock broke above the upper band. In 37 of the 43 cases the stock fell afterwards. This puts the odds of success at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on VSTM as a result. In 72 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for VSTM just turned positive on October 15, 2026. Looking at past instances where VSTM's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.

VSTM moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +23.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 146 of 188 cases where VSTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.686) is normal, around the industry mean (2.988). P/E Ratio (-3.775) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 58 to 132.95B. VRTX holds the highest valuation in this group at 132.95B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -15%. SLN experienced the highest price growth at 119%, while EYPT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -21%. For the same stocks of the Industry, the average monthly volume growth was 5% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
VSTM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company that discovers and develops drugs

Industry Biotechnology

Industry
Biotechnology
Address
117 Kendrick Street
Phone
+1 781 292-4200
Employees
104
Web
https://www.verastem.com
VSTM in downward trend: price may drop because broke its higher Bollinger Band on October 20, 2026